Primary lung tumors in dogs, though rare, are becoming more recognized due to advancements in veterinary diagnostics and longer canine lifespans. Early detection plays a.
Merck Animal Health has introduced a groundbreaking immunotherapy for canine cancer called gilvetmab. This checkpoint inhibitor specifically designed for dogs targets the PD-1 protein, reactivating.